Publikace












            ******************************************************************************************

            *
            ******************************************************************************************


             
            Pohled do databáze evidence publikační činnosti v systému OBD [ URL "https://obd3.lf3.cuni
            verso.fpl?fname=obd_public&public_id=&public_id=361&_autor_org_podriz=2394"] .


            Ve výpisu jsou záznamy publikací s afiliací k 3. LF UK






            *=========================================================================================
            * Vybrané publikace kliniky

            *=========================================================================================

            • Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z, Burman J, Moore J,

              Wulffraat NM, Kazmi M, Greco R, Snarski E, Kozak T, Kirgizov K, Alexander T, Bader P, Sa
              D. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation
              autoimmune diseases. [ URL "https://www.ncbi.nlm.nih.gov/pubmed/29296926"] Blood Adv 201


            • Novak J, Havrda M, Gaherova L, Spicka J, Kozak T. Clinical case: idelalisib-induced immu
              flare. [ URL "https://www.ncbi.nlm.nih.gov/pubmed/28523957"] Immunopharmacol Immunotoxic

              2017;39:251-252.
            • Vojdeman FJ, Herman SEM, Kirkby N, Wiestner A, van T' Veer MB, Tj?nnfjord GE, Itälä-Reme
              Farooqui MZ, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, Kozak T, Walewsk

              Testroote MCJ, van Oers MHJ, Geisler CH, Niemann CU. Soluble CD52 is an indicator of dis
              in chronic lymphocytic leukemia. [ URL "https://www.ncbi.nlm.nih.gov/pubmed/28278728"] L
              2017;58:2356-2362.


            • Novak J, Dobrovolny J, Brozova J, Novakova L, Kozak T. Recovery of mucosal-associated in
              cells after myeloablative chemotherapy and autologous peripheral blood stem cell transpl

              "https://www.ncbi.nlm.nih.gov/pubmed/26409838"] Clin Exp Med 2016;16:529-537.

            • Bröckelmann PJ, Goergen H, Kohnhorst C, von Tresckow B, Moccia A, Markova J, Meissner J,

              Ludwig WD, Fuchs M, Borchmann P, Engert A. Late Relapse of Classical Hodgkin Lymphoma: A
              the German Hodgkin Study Group HD7 to HD12 Trials. [ URL "https://www.ncbi.nlm.nih.gov/p
              J Clin Oncol 2017;35:1444-1450.


            • Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M
              Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, B

              H, Fuchs M, Diehl V, Engert A. Progression-free survival of early interim PET-positive p
              advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination 
              (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Stu

              "https://www.ncbi.nlm.nih.gov/pubmed/28236583"] Lancet Oncol 2017;18:454-463.

            • Mocikova H, Pytlik R, Sykorova A, Janikova A, Prochazka V, Vokurka S, Berkova A, Belada 

              Buresova L, Trneny M; Czech Lymphoma Study Group. Role of rituximab in treatment of pati
              primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma 
              registry. [ URL "https://www.ncbi.nlm.nih.gov/pubmed/27087066"] Leuk Lymphoma 2016;57:27


            • Markova J, Kahraman D, Kobe C, Skopalova M, Mocikova H, Klaskova K, Dedeckova K, Eich HT
              Dietlein M, Kozak T. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography

              and late therapy assessment of patients with advanced Ho dgkin lymphoma treated with ble
              etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. [ URL
              www.ncbi.nlm.nih.gov/pubmed/21740300"] Leuk Lymphoma 2012;53:64-70.